BGI
RARE icon

B Group Inc’s Ultragenyx Pharmaceutical RARE Stock Holding History

B Group Inc’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-67,600
Closed -$2.46M – 21
2025
Q2 		$2.46M Buy
67,600
+30,000
+80% +$1.08M 1.89% 13
2025
Q1 		$1.36M Buy
37,600
+8,100
+27% +$337K 1.17% 13
2024
Q4 		$1.24M Buy
+29,500
New +$1.46M 0.76% 11

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

B Group Inc's RARE Position: Q2 2026 in Review

B Group Inc held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 135,000 shares worth $4.51M. The position accounts for 2.12% of the portfolio, ranked #17.

B Group Inc first reported a position in RARE in Q4 2024 and has held it in 7 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • B Group Inc held 135,000 shares of Ultragenyx Pharmaceutical worth $4.51M as of Q2 2026.
  • B Group Inc left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
  • Ultragenyx Pharmaceutical made up 2.12% of B Group Inc's portfolio in Q2 2026, its #17 holding.
  • B Group Inc first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.